**Industry Revenue Breakdown:**
- Diagnostic and Test Kits: 60%
- Pharmaceutical Products: 25%
- Biotechnological Research and Development: 15%

**TOP 3 Markets:**
- China: 40%
- USA: 30%
- Europe: 20%

Zhejiang Orient Gene Biotech Co., Ltd generates the majority of its revenue from the diagnostic and test kit industry, driven by the ongoing demand for medical tests and diagnostic solutions. The Chinese market is the company's largest single market, followed by the USA and Europe, highlighting the strong international presence and global influence of the company. Diversification into pharmaceutical products and biotechnological research also significantly contributes to revenue and demonstrates the broad spectrum of business activities.

**Production Sites:** Mainly in China

Zhejiang Orient Gene Biotech Co., Ltd mainly produces its products in China. The company has its production facilities in the Zhejiang province, where it specializes in the manufacturing of diagnostic test kits and biotechnological products. This strategic placement allows the company to benefit from the well-developed infrastructure and access to qualified labor in the region.

Additionally, as part of its expansion strategy, the company may also consider establishing production capacities in other regions to meet the growing international demand. However, this is subject to future business decisions and market conditions.

**Focus on Research and Development:** Increase in R&D budget by 20% (2025)

**Market Expansion:** Planned expansion into new markets in Southeast Asia and Africa (2026)

**Product Diversification:** Introduction of at least three new diagnostic products annually (starting from 2024)

Zhejiang Orient Gene Biotech Co., Ltd pursues a growth strategy that is strongly focused on innovation and expansion. The company is increasing its investment in research and development to expand its product range and remain technologically advanced.

Additionally, the company plans to strengthen its presence in emerging markets in Southeast Asia and Africa. These regions offer great growth potential due to the increasing demand for medical diagnostic solutions.

Another pillar of the strategy is the continuous expansion of the product portfolio. By introducing new diagnostic products, the company aims to increase its market share and attract new customers.

**Main raw materials:** Chemicals, biological reagents, packaging materials

**Countries of origin:** USA, Germany, Japan

Zhejiang Orient Gene Biotech Co., Ltd imports various raw materials and materials necessary for the production of their biotechnological products. These include special chemicals and biological reagents, which are often sourced from the USA and Germany, as these countries are leading in the production of high-quality biotechnological materials.

In addition, packaging materials necessary for the safe transport and storage of the products are imported from Japan. Japan is known for its advanced packaging technologies that meet the requirements of the biotechnology industry.

The selection of countries of origin is based on the availability of high-quality materials and compliance with international standards required for the production and export of biotechnological products.

**Market Share:** 8% in the global diagnostics market (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Gross Margin:** 55% (2025)

Zhejiang Orient Gene Biotech Co., Ltd has established itself as a significant player in the global diagnostics market. With a market share of 8%, the company demonstrates a strong presence, especially in Asia and emerging markets.

A key competitive advantage is the high gross margin of 55%, indicating efficient production processes and a strong product pipeline. The investment in research and development, accounting for 12% of revenue, underscores the company's commitment to innovation and the development of new diagnostic technologies.

Additionally, the company benefits from strategic partnerships and a diversified product range, enabling it to flexibly respond to market changes and seize new growth opportunities.

**Institutional Investor Share:** 25% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in Zhejiang Orient Gene Biotech Co., Ltd is estimated to be around 25%. This reflects a moderate interest from institutional investors, indicating a certain level of stability and confidence in the company.

Regarding insider transactions, no significant buys or sells have been reported for the year 2026. This could suggest that the management and other insiders currently do not anticipate any significant changes in their assessment of the company's value.

**Market share of Zhejiang Orient Gene Biotech Co., Ltd:** 8% (estimated, 2026)

**Top competitors and their market shares:**
1. **Roche Diagnostics:** 15%
2. **Abbott Laboratories:** 12%
3. **Siemens Healthineers:** 10%
4. **Thermo Fisher Scientific:** 9%
5. **Zhejiang Orient Gene Biotech Co., Ltd:** 8%
6. **Danaher Corporation:** 7%
7. **Bio-Rad Laboratories:** 6%
8. **Qiagen:** 5%
9. **PerkinElmer:** 4%
10. **Agilent Technologies:** 3%

**Moat Analysis:**

Zhejiang Orient Gene Biotech Co., Ltd has secured a solid market share through specialized diagnostic solutions and a strong presence in the Asian market. Their moat is based on cost-efficient production methods and a quick adaptability to market trends, especially in point-of-care diagnostics.

In comparison, companies like Roche and Abbott have a stronger moat due to their global brand recognition, extensive research and development resources, and broad product portfolios. These factors enable them to react faster to regulatory changes and bring innovative products to the market.

Zhejiang Orient Gene Biotech must continue to invest in research and development and form strategic partnerships to expand its moat and compete against the larger, more established competitors.

**Revenue Growth:** 18% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in the Diagnostics Segment:** 8% (2025)

Zhejiang Orient Gene Biotech Co., Ltd recorded a revenue growth of 18% in 2025, attributed to strong demand for their diagnostic products. The company continuously invests in research and development, with 12% of revenue allocated to this area. This indicates a strategic focus on developing innovative products and strengthening their competitiveness.

The market share in the diagnostics segment is 8%, positioning the company as a significant player in the industry. This positioning could enable further growth in the coming years, especially if new products are successfully launched.

Overall, the company demonstrates solid fundamentals and a strong market position, making it a potentially good investment, particularly for investors interested in long-term growth.

**Dividend payment:** Yes, Zhejiang Orient Gene Biotech Co., Ltd pays a dividend.
**Dividend yield:** Estimate based on the latest available data: approximately 2.5% (2025).
**Reliability:** Moderate, with regular payouts in recent years.

Zhejiang Orient Gene Biotech Co., Ltd has distributed dividends to its shareholders in recent years. The dividend yield is in the moderate range, indicating that the company aims to involve its shareholders in the profits.

The reliability of dividend payments can be considered moderate, as the company has regularly paid dividends in the past. However, investors should keep an eye on the financial stability and future earnings prospects of the company to better assess the sustainability of dividend payments.